Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
| Autor: | C. J. A. Punt, U. Keilholz, Jantien Wanders, Yves Humblet, Wim H. J. Kruit, G. Stoter, L. Håkansson, J. Uiters, Bernard Escudier, Peter F.A. Mulders, C. Scheibenbogen, Marie-Françoise Avril, A. M. M. Eggermont, M. Delire, N. van Baren, Marie Marchand, Thierry Boon, Steinar Aamdal |
|---|---|
| Přispěvatelé: | Other departments, Medical Oncology, Surgery |
| Rok vydání: | 2003 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Skin Neoplasms medicine.medical_treatment Cancer Vaccines Metastasis Adjuvants Immunologic SDG 3 - Good Health and Well-being Antigens Neoplasm Internal medicine Carcinoma Non-Small-Cell Lung Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Melanoma Aged Carcinoma Transitional Cell business.industry Cancer Immunotherapy gene therapy and transplantation [UMCN 1.4] Immunotherapy Middle Aged Saponins medicine.disease QS21 Survival Analysis Recombinant Proteins Neoplasm Proteins Vaccination Lipid A Treatment Outcome Urinary Bladder Neoplasms Immunology Female Immunization business Complication Adjuvant |
| Zdroj: | European Journal of Cancer, 39, 1, pp. 70-7 European journal of cancer (Oxford, England, 39(1), 70-77. Elsevier Limited European Journal of Cancer, 39, 70-7 European Journal of Cancer, 39(1), 70-77. Elsevier Ltd. |
| ISSN: | 0959-8049 |
| Popis: | Item does not contain fulltext Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect